These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 36722405)

  • 1. Leukemic stem cells and therapy resistance in acute myeloid leukemia.
    Stelmach P; Trumpp A
    Haematologica; 2023 Feb; 108(2):353-366. PubMed ID: 36722405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukemic stem cell signatures in Acute myeloid leukemia- targeting the Guardians with novel approaches.
    Thakral D; Gupta R; Khan A
    Stem Cell Rev Rep; 2022 Jun; 18(5):1756-1773. PubMed ID: 35412219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia.
    Craddock C; Quek L; Goardon N; Freeman S; Siddique S; Raghavan M; Aztberger A; Schuh A; Grimwade D; Ivey A; Virgo P; Hills R; McSkeane T; Arrazi J; Knapper S; Brookes C; Davies B; Price A; Wall K; Griffiths M; Cavenagh J; Majeti R; Weissman I; Burnett A; Vyas P
    Leukemia; 2013 Apr; 27(5):1028-36. PubMed ID: 23223186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-based and antibody-mediated immunotherapies directed against leukemic stem cells in acute myeloid leukemia: Perspectives and open issues.
    Valent P; Bauer K; Sadovnik I; Smiljkovic D; Ivanov D; Herrmann H; Filik Y; Eisenwort G; Sperr WR; Rabitsch W
    Stem Cells Transl Med; 2020 Nov; 9(11):1331-1343. PubMed ID: 32657052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Convergent epigenetic evolution drives relapse in acute myeloid leukemia.
    Nuno K; Azizi A; Koehnke T; Lareau C; Ediriwickrema A; Corces MR; Satpathy AT; Majeti R
    Elife; 2024 Apr; 13():. PubMed ID: 38647535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients.
    Paprocka M; Bielawska-Pohl A; Rossowska J; Krawczenko A; Duś D; Kiełbiński M; Haus O; Podolak-Dawidziak M; Kuliczkowski K
    Eur J Haematol; 2017 Nov; 99(5):415-422. PubMed ID: 28805931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive Chemotherapy.
    Winters AC; Bosma G; Abbott D; Minhajuddin M; Jordan C; Pollyea DA; Gutman JA
    Transplant Cell Ther; 2022 Oct; 28(10):694.e1-694.e9. PubMed ID: 35902048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.
    Gentles AJ; Plevritis SK; Majeti R; Alizadeh AA
    JAMA; 2010 Dec; 304(24):2706-15. PubMed ID: 21177505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.
    Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C
    Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Changes of Leukemia Stem Cells in Acute Myeloid Leukemia before and after Treatment].
    Lv JT; Yang ZG; Guang YH; Lin ZS; Xiao XX; Liu D; Shi M; Wang WS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):658-664. PubMed ID: 29950200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations.
    Desikan SP; Ravandi F; Pemmaraju N; Konopleva M; Loghavi S; Jabbour EJ; Daver N; Jain N; Chien KS; Maiti A; Montalban-Bravo G; Kadia TM; Macaron W; DeLumpa R; Kwari M; Borthakur G; Short NJ
    Acta Haematol; 2022; 145(5):529-536. PubMed ID: 35717939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can we selectively target AML stem cells?
    Jordan CT
    Best Pract Res Clin Haematol; 2019 Dec; 32(4):101100. PubMed ID: 31779978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
    Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients.
    Almohsen F; Al-Mudallal SS
    Cardiovasc Hematol Disord Drug Targets; 2020; 20(2):145-151. PubMed ID: 31438833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
    de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
    Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An arms-race against resistance: leukemic stem cells and lineage plasticity.
    Waclawiczek A; Leppä AM; Renders S; Trumpp A
    Mol Oncol; 2024 Mar; 18(3):475-478. PubMed ID: 38375990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escape From Treatment; the Different Faces of Leukemic Stem Cells and Therapy Resistance in Acute Myeloid Leukemia.
    van Gils N; Denkers F; Smit L
    Front Oncol; 2021; 11():659253. PubMed ID: 34012921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemic Stem Cells: From Leukemic Niche Biology to Treatment Opportunities.
    Marchand T; Pinho S
    Front Immunol; 2021; 12():775128. PubMed ID: 34721441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax + Azacitidine by Targeting Fatty Acid Desaturases 1 and 2.
    Culp-Hill R; Stevens BM; Jones CL; Pei S; Dzieciatkowska M; Minhajuddin M; Jordan CT; D'Alessandro A
    Metabolites; 2023 Mar; 13(4):. PubMed ID: 37110126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia.
    He L; Arnold C; Thoma J; Rohde C; Kholmatov M; Garg S; Hsiao CC; Viol L; Zhang K; Sun R; Schmidt C; Janssen M; MacRae T; Huber K; Thiede C; Hébert J; Sauvageau G; Spratte J; Fluhr H; Aust G; Müller-Tidow C; Niehrs C; Pereira G; Hamann J; Tanaka M; Zaugg JB; Pabst C
    EMBO Mol Med; 2022 Apr; 14(4):e14990. PubMed ID: 35253392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.